Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Is past as of Friday the money is clear to flow in, and I'm pretty sure that's exactly what it'll do. No reason hold back now. Over to you Adam, make us all better off please! It'd be great if there was an early doors deal to be announced as the poster below said, but my gut feel is all will go quiet for a while until we get a big contract land, NHS testing finalises / CE testing etc.
The June tip of the Month: Buy Vialogy at a 0.17p offer – one month target 0.255p to sell Not one but three members of the HotStockRockets team have interests in this stock but we will not sell until at least 24 hours after advising you to do so. And we reckon that if you buy today you will be making a 50% return within a month. Vialogy (LSE:VIY) is our tip of the month at a 0.17p offer. This AIM listed company used to be a total joke of a lifestyle company, pretending that it had new technology in oil. Thankfully at death’s door it was rescued by well-known turnaround/cash shell expert Adam Reynolds. The shares came back from suspension a couple of weeks ago as Reynolds announced a transformational RTO. That will be ratified at an EGM this Thursday which will also approve a 100 for 1 share consolidation (which will narrow the spread) and a change of name to Premaitha. The maths. The company raised £6.5 million at 0.11p. It also issued £10.5 million of shares at 0.11p to buy Premaitha. The shareholders of Premaitha are locked in and the placees are all institutional so can’t flip like a private investor and so are effectively locked in. The placing was FOUR times oversubscribed. Thus with another institutional placing done earlier this year by Reynolds the free float is sub 10%. The shares have been hit since the return from suspension by some in the free float selling ordinaries to pay for participation in a 1 for 4 open offer. There is now no time left for any more such flipping. The market capitalisation is now – at 0.17p to buy – £29 million and net cash is c£8 million. So how do you justify an EV of £21 million? Easy. 1. Management. The Premaitha team is headed up by an accomplished CEO Stephen Little but also has on board David Evans. Many years ago he turned Axis Shield from a penny stock into an £8 stock. He knows this industry and has a mass City following so we expect institutional buying post the EGM 2. The company is working on the final development and commercialisation of a non-invasive pre-natal screening test for Down’s syndrome developed by Premaitha. This is a massive market. Of course there are risks in medical technology but we back Evans and the size of this global market is estimated to be $4.2 billion. We are assured that Vialogy needs no more ash to get its product to market and you do not need much of a market share to justify the EV here. Reasons to buy now: 1. The shares have been depressed by small investors selling ordinaries to take up the open offer. That process is now over. 2. Management. Enough said. 3. Post EGM we expect institutional buying from those who were massively scaled back in the placing and there is a relatively small free float. 4. We expect that with a news blackout for several months there is a pipeline of RNS announcements which will start very soon after the EGM
David is an entrepreneurial accountant focusing on diagnostic and life science companies. He has a plethora of Chairman and Non Executive roles across the sector including Epistem Holdings plc, Omega Diagnostics Group plc, EKF Diagnostic Holdings plc and Scancell Holdings plc. David was the former Chairman of DxS and oversaw the acquisition by QIAGEN in 2009. He was the Joint MD of Axis Shield and was responsible for the merger. David holds an MBA from University of Dundee.
He is the former CEO of DxS, an innovator in the field of personalised medicine, developing and manufacturing companion diagnostics. DxS was funded with £3.5M in 2001 and was sold to QIAGEN BV in 2009 for £85M. That's a massive return on investment. This guy doesn't mess about, multibagger coming here. Buy and hold.
Showing now.
PMd ya.
Thanks for this.
Vanvagabond- appreciated
The study, which launched on 1 November 2013, will involve the recruitment of women from several maternity units in London and South East England. It will investigate how NIPT compares with the NHS’s current Down syndrome screening programme in terms of how many women want it; how easily the NHS can provide it and how the associated information and education would be provided to women and healthcare professionals. The launch of the study created considerable media interest, some of which can be accessed via the links below. http://www.bbc.co.uk/news/health-24755589 http://www.itv.com/news/update/2013-11-01/downs-syndrome-blood-test-to-be-trialled-in-nhs/
I'll be honest I'm not arsed about their target price. Just imagine what will happen to this share when the first inkling,the first snifter of NHS involvement is confirmed. Transformational.
I think when the company announces a major contract win or sign a new partner they will increase there target price. With the current buying we might get to .25 by Friday or 25p when shares are consolidated.
I keep revisiting these two sources of info: http://www.telegraph.co.uk/health/healthnews/10676672/Downs-syndrome-screening-NHS-could-soon-offer-far-more-reliable-test-for-pregnant-women.html Reference to our running the study: http://www.osprea.ox.ac.uk/wp-content/uploads/2013/07/PIL_kelly_v5-0_6mar14.docx
That's their strategy, so the sell price is just a set figure. Although target of 50% in this instance in a month. GLA
I agree,there target is a bit low,considering the director cant sell until 50p. Reckon it could go beyond there target by end of week. Should be more buyers reading the newsletter as they get home from work & buying in tomorrow.
Excellent article only flawed by recommending to sell at 25p. This has vastly more potential than that.
I agree that is a buy, sp would have dropped down alot if it wasn't. Again it could be from the hotstocks tip released today
was at 1.31 when it was .17v .19 so I would think a buy as went back up after. good confidence showing last few days of trading.. can see us above .20 tomorrow..
There was a delayed 20 Million trade,not sure if it was a buy or sell at 16.31.
Adam Reynolds has a very big option package which only kicks in if the shares trade above 0.5p (50p post consolidation) for 30 consecutive days. As a promoter of repute we expect him to work his socks off from the moment the EGM is over to get his options. The Trade: Buy at 0.17p and up to 0.2p with a one month target to sell of 0.255p. -----
The June tip of the Month: Buy Vialogy at a 0.17p offer – one month target 0.255p to sell Not one but three members of the HotStockRockets team have interests in this stock but we will not sell until at least 24 hours after advising you to do so. And we reckon that if you buy today you will be making a 50% return within a month. Vialogy (LSE:VIY) is our tip of the month at a 0.17p offer. This AIM listed company used to be a total joke of a lifestyle company, pretending that it had new technology in oil. Thankfully at death’s door it was rescued by well-known turnaround/cash shell expert Adam Reynolds. The shares came back from suspension a couple of weeks ago as Reynolds announced a transformational RTO. That will be ratified at an EGM this Thursday which will also approve a 100 for 1 share consolidation (which will narrow the spread) and a change of name to Premaitha. The maths. The company raised £6.5 million at 0.11p. It also issued £10.5 million of shares at 0.11p to buy Premaitha. The shareholders of Premaitha are locked in and the placees are all institutional so can’t flip like a private investor and so are effectively locked in. The placing was FOUR times oversubscribed. Thus with another institutional placing done earlier this year by Reynolds the free float is sub 10%. The shares have been hit since the return from suspension by some in the free float selling ordinaries to pay for participation in a 1 for 4 open offer. There is now no time left for any more such flipping. The market capitalisation is now – at 0.17p to buy – £29 million and net cash is c£8 million. So how do you justify an EV of £21 million? Easy. 1. Management. The Premaitha team is headed up by an accomplished CEO Stephen Little but also has on board David Evans. Many years ago he turned Axis Shield from a penny stock into an £8 stock. He knows this industry and has a mass City following so we expect institutional buying post the EGM 2. The company is working on the final development and commercialisation of a non-invasive pre-natal screening test for Down’s syndrome developed by Premaitha. This is a massive market. Of course there are risks in medical technology but we back Evans and the size of this global market is estimated to be $4.2 billion. We are assured that Vialogy needs no more ash to get its product to market and you do not need much of a market share to justify the EV here. Reasons to buy now: 1. The shares have been depressed by small investors selling ordinaries to take up the open offer. That process is now over. 2. Management. Enough said. 3. Post EGM we expect institutional buying from those who were massively scaled back in the placing and there is a relatively small free float. 4. We expect that with a news blackout for several months there is a pipeline of RNS announcements which will start very soon after the EGM 5. Adam Reynolds has a very big option package which only kicks in if
Will take time. Buy and hold!
The allowed buyers at. 11 will be subject to a CGTax upon sale. So just. Forget about this. 11, its a AR thank you to current investors and those onvestors will I think be holding for a slice of 4 billion, that will take te
I think some investors who get home tonight will read the hot-stock news letter & buy in tomorrow morning. So might see even bigger rises tomorrow. Might push .20p by closing.
ille second that.
the placing allocated to Pi,s is very small with most going to institutional investors. my opinion is that yes some will traders but they will get snapped up. The last placing when adam reynolds took over was at 0.1 and the sp went onto spike at 0.25 shortly afterwards. target is 50p same as bods.